¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
°æ¸· ´ëü¹° ½ÃÀå ¼ºÀå°ú µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, °æ¸· ´ëü¹° ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 2¾ï 8,768¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 3.63%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°æ¸· ´ëü¹° »ê¾÷Àº Àü ¼¼°è ½Å°æ¿Ü°ú ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. ¼¼°è½Å°æÇп¬¸ÍÀÌ 2023³â 10¿ù¿¡ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é, ÃÖ±Ù ¼¼°è Áúº´ºÎ´ã(GBD) Á¶»ç¿¡ µû¸£¸é, ½Å°æ°è ÁúȯÀº Àü ¼¼°èÀûÀ¸·Î »ç¸Á¿øÀÎ 2À§À̸ç, Àå¾ÖÀÇ ÁÖ¿ä ¿øÀÎÀ¸·Î ¹àÇôÁ³½À´Ï´Ù. ÇöÀç Àα¸ÀÇ 40% ÀÌ»óÀÌ ÀÌ ÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, ÀÌ À¯º´·üÀº 2050³â±îÁö °ÅÀÇ µÎ ¹è·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ, Àü ¼¼°è °í·ÉÈ, ¿Ü»ó¼º ³ú¼Õ»ó ¹ß»ý·ü Áõ°¡, ¿Ü°úÀû °³ÀÔÀÌ ÇÊ¿äÇÑ ÁßÃ߽Űæ°è Á¾¾çÀº ÀÌ·¯ÇÑ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. À¯¿£¿¡ µû¸£¸é, 2023³â 1¿ù, Àü ¼¼°è 65¼¼ ÀÌ»ó ³ëÀÎ Àα¸´Â 2021³â 7¾ï 6,100¸¸ ¸í¿¡¼ 2050³â ¾à 16¾ï ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ °í·ÉÃþÀº ½Å°æÁúȯ¿¡ °É¸®±â ½¬¿ö ½Å°æÇÐÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ¶ÇÇÑ, ÃÖ¼Òħ½ÀÀû ½Ã¼úÀ» Æ÷ÇÔÇÑ ½Å°æ¿Ü°úÀû ½Ã¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ »ýüÀûÇÕ¼º ¹× È¿°úÀûÀÎ °æ¸· ´ëü¹°ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ, ÇÕ¼º °æ¸· ´ëü¹°Àº ±âÁ¸ÀÇ ÀÚ°¡ À̽ÄÀç¿¡ ºñÇØ ¿ì¼öÇÑ Æ¯¼ºÀ¸·Î ÀÎÇØ ¸¹Àº »ç¶ûÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¹ßÆ÷ Æú¸®Åׯ®¶óÇ÷ç¿À·Î¿¡Æ¿·»(ePTFE)À̳ª ½Ç¸®ÄÜÀ¸·Î ¸¸µé¾îÁø ÇÕ¼º ´ëü °æ¸·Àº ¾ÈÁ¤µÈ ǰÁú, ¼ö¼ú ½Ã°£ ´ÜÃà, °ø¿© ºÎÀ§ ÀÌȯÀ² ÃÖ¼ÒÈ µîÀÇ ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. ¹Ý¸é, ³ôÀº »ýüÀûÇÕ¼º°ú ¸é¿ª¹ÝÀÀ °¨¼Ò°¡ ÇÊ¿äÇÑ °æ¿ì¿¡´Â ¼Ò³ª µÅÁö À¯·¡ÀÇ »ý¹°ÇÐÀû ´ëü¹°ÀÌ ¼±È£µË´Ï´Ù. ÀÓ»ó Àû¿ëÀÇ È®´ë¿Í ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ °ü½ÉÀÇ Áõ°¡´Â ÀÌ·¯ÇÑ Ã·´Ü Àç·áÀÇ ½ÃÀå ¼ºÀåÀ» Å©°Ô ÃËÁøÇϰí ÀÖÀ¸¸ç, ¼±Áø±¹°ú ½ÅÈï±¹ ¸ðµÎ¿¡¼ ´õ ³ªÀº ¼ö¿ëÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.
±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú À¯¸®ÇÑ »óȯ Á¤Ã¥µµ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀ¸·Î ±â¿©Çϰí ÀÖÀ¸¸ç, FDA ¹× À¯·´ CE¿Í °°Àº ±â°üÀº °æ¸· ´ëü¹°¸¦ ½ÂÀÎÇÏ¿© ´Ù¾çÇÑ ½Å°æ¿Ü°úÀû ¿ëµµ¿¡ ´ëÇÑ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼ö¼ú ÈÄ ÇÕº´Áõ °¨¼Ò ¹× ȸº¹ ½Ã°£ ´ÜÃà°ú °°Àº ÀÌ·¯ÇÑ ´ëüǰÀÇ ÀÌÁ¡¿¡ ´ëÇÑ ÀÇ·áÁøÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó º´¿ø ¹× Àü¹® ¼ö¼ú ¼¾ÅÍ¿¡¼ÀÇ Ã¤ÅÃÀÌ ´õ¿í Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°æ¸· ´ëü¹° ½ÃÀå ºÐ¼® °³¿ä
- À¯Çüº°·Î´Â »ý¹°ÇÐÀû °æ¸· ´ëü¹° ºÐ¾ß°¡ »ýºÐÇØ¼º ¹× ¼±ÃµÀû Á¶Á÷°ú È¿°úÀûÀ¸·Î ÅëÇյǴ ´É·Â°ú °°Àº ¸î °¡Áö ÀåÁ¡À¸·Î ÀÎÇØ °¡Àå Å« ¼öÀÍ Á¡À¯À²·Î ¾÷°è¸¦ Áö¹èÇϰí ÀÖ½À´Ï´Ù.
- ºÏ¹Ì´Â 2024³â 32.89%·Î °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ¼ö¼ú ÈÄ Ä¡À¯¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¼±ÁøÈµÈ ÀÇ·á ÀÎÇÁ¶ó, ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç, ÷´Ü °æ¸· ´ëü ¼Ö·ç¼Ç¿¡ ´ëÇÑ Á¢±Ù¼º µîÀÌ ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.
- °æ¸· ´ëü¹° ½ÃÀå¿¡ ÁøÃâÇÑ ±â¾÷À¸·Î´Â Medtronic, B. Brown SE, Striker, DePuy Synthetics(Johnson & Johnson), W.L. Gore & Associates, Acera Surgical, Severn Healthcare Technologies, Integra Life Sciences, Gunze µîÀÌ ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ºÐ¼® ¹æ¹ý¡¤¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå °æ¸· ´ëü¹° ½ÃÀå : º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå ¿¬°ü Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ½ÃÀå ±âȸ ºÐ¼®
- ½ÃÀå °úÁ¦ ºÐ¼®
- °æ¸· ´ëü¹° ½ÃÀå : ºÐ¼® Åø
- ¾÷°è ºÐ¼® : Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå °æ¸· ´ëü¹° ½ÃÀå : Á¾·ùº° ÃßÁ¤°ú µ¿Ç⠺м®
- ºÎ¹®º° ´ë½Ãº¸µå
- °æ¸· ´ëü¹° ½ÃÀå : Á¾·ùº° µ¿Ç⠺м®
- °æ¸· ´ëü¹° ½ÃÀå : ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м®, Á¾·ùº°(2018-2030³â)
- »ý¹°ÇÐÀû °æ¸· ´ëü¹°
- ÇÕ¼º °æ¸· ´ëü¹°
Á¦5Àå °æ¸· ´ëü¹° ½ÃÀå : Áö¿ªº° ÃßÁ¤Ä¡¿Í µ¿Ç⠺м®(Á¾·ùº°)
- Áö¿ªº° ´ë½Ãº¸µå
- ½ÃÀå ±Ô¸ð ¿¹Ãø°ú µ¿Ç⠺м®(2018-2030³â)
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- µ§¸¶Å©
- ½º¿þµ§
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- Çѱ¹
- È£ÁÖ
- ű¹
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦6Àå °æÀï ±¸µµ
- ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
- ÁÖ¿ä ±â¾÷ °³¿ä
- Medtronic
- B. Braun SE
- Stryker
- DePuy Synthes(Johnson & Johnson)
- WL Gore & Associates, Inc.
- Acera Surgical Inc.
- Severn Healthcare Technologies Limited.
- INTEGRA LIFESCIENCES
- GUNZE LIMITED.
KSM 25.02.28
Dura Substitutes Market Growth & Trends:
The global dura substitutes market size is anticipated to reach USD 287.68 million by 2030 and is projected to grow at a CAGR of 3.63% over the forecast period, according to a new report by Grand View Research, Inc. The dura substitute industry is experiencing significant growth due to the increasing prevalence of neurosurgical disorders worldwide. According to an article published by the World Federation of Neurology in October 2023, a recent Global Burden of Disease (GBD) study reveals that neurological disorders are the second leading cause of death and the primary cause of disability globally. Currently, over 40% of the population is affected by these conditions, with projections indicating this prevalence can almost double by 2050.
Moreover, the global aging population, rising incidence of traumatic brain injuries, and central nervous system tumors requiring surgical interventions are driving demand for these products. According to the United Nations, in January 2023, the global geriatric population aged 65 years and above is expected to increase from 761 million in 2021 to approximately 1.6 billion in 2050. This elderly population is more vulnerable to neurological disorders, which can increase the demand for neurological procedures. In addition, advancements in neurosurgical techniques, including minimally invasive procedures, have increased the need for biocompatible and effective dura substitutes.
Moreover, the adoption of synthetic dura substitutes is gaining traction due to their superior properties compared to traditional autologous grafts. Synthetic substitutes, such as those made from expanded polytetrafluoroethylene (ePTFE) or silicone, offer consistent quality, reduced operative time, and minimized donor-site morbidity. Meanwhile, biological substitutes derived from bovine or porcine sources are preferred in cases requiring high biocompatibility and reduced immune response. The combination of expanding clinical applications and an increasing focus on patient safety is significantly driving the market for these advanced materials, enabling better acceptance in both developed and emerging economies.
Regulatory approvals and favorable reimbursement policies are also positively contributing to market growth. Agencies such as the FDA and European CE are recognizing dura substitutes, ensuring their safety and efficacy for a broad range of neurosurgical applications. Moreover, growing awareness among healthcare providers regarding the benefits of these substitutes, including reduced postoperative complications and faster recovery times, has further increased their adoption in hospitals and specialized surgical centers, which is further expected to drive the market growth over the forecast period.
Dura Substitutes Market Report Highlights:
- Based on type, the biological dura substitutes segment dominated the industry with the largest revenue share owing to its several advantages, such as its biodegradable nature and ability to effectively integrate with native tissues.
- North America held the largest market share of 32.89% in 2024. This can be attributed to increasing awareness about post-surgical healing, developed healthcare infrastructure, presence of key market players, and access to advanced dura substitute solutions.
- Market players operating in dura substitutes market include Medtronic; B. Braun SE; Stryker; DePuy Synthes (Johnson & Johnson); W. L. Gore & Associates, Inc.; Acera Surgical Inc.; Severn Healthcare Technologies Limited.; INTEGRA LIFESCIENCES; GUNZE LIMITED.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.4. Information or Data Analysis
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Dura Substitutes Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising Incidents of Neurological Disorders
- 3.2.1.2. Rising Awareness About Minimally Invasive Procedures
- 3.2.1.3. Growing Geriatric Population
- 3.2.1.4. Increasing Regulatory Support
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Risk of Complications and Safety Concerns
- 3.2.2.2. High Cost of Dura Substitutes
- 3.2.3. Market Opportunities Analysis
- 3.2.3.1. Expansion in Emerging Markets
- 3.2.4. Market Challenge Analysis
- 3.2.4.1. Limited Availability of High-Quality Biological Materials
- 3.3. Dura Substitutes Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's Five Forces
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political & Legal Landscape
- 3.3.2.2. Economic and Social Landscape
- 3.3.2.3. Technological landscape
Chapter 4. Dura Substitutes Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Dura Substitutes Market Type Movement Analysis
- 4.3. Dura Substitutes Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
- 4.4. Biological Dura Substitutes
- 4.4.1. Biological Dura Substitutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Synthetic Dura Substitutes
- 4.5.1. Synthetic Dura Substitutes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Dura Substitutes Market: Regional Estimates & Trend Analysis By Type
- 5.1. Regional Dashboard
- 5.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
- 5.3. North America
- 5.3.1. North America Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.2. U.S.
- 5.3.2.1. Key Country Dynamics
- 5.3.2.2. Competitive Scenario
- 5.3.2.3. Regulatory Scenario
- 5.3.2.4. Reimbursement Scenario
- 5.3.2.5. U.S. Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.3. Canada
- 5.3.3.1. Key Country Dynamics
- 5.3.3.2. Competitive Scenario
- 5.3.3.3. Regulatory Scenario
- 5.3.3.4. Reimbursement Scenario
- 5.3.3.5. Canada Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.3.4. Mexico
- 5.3.4.1. Key Country Dynamics
- 5.3.4.2. Competitive Scenario
- 5.3.4.3. Regulatory Scenario
- 5.3.4.4. Reimbursement Scenario
- 5.3.4.5. Mexico Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Europe
- 5.4.1. Europe Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.2. UK
- 5.4.2.1. Key Country Dynamics
- 5.4.2.2. Competitive Scenario
- 5.4.2.3. Regulatory Scenario
- 5.4.2.4. Reimbursement Scenario
- 5.4.2.5. UK Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.3. Germany
- 5.4.3.1. Key Country Dynamics
- 5.4.3.2. Competitive Scenario
- 5.4.3.3. Regulatory Scenario
- 5.4.3.4. Reimbursement Scenario
- 5.4.3.5. Germany Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.4. France
- 5.4.4.1. Key Country Dynamics
- 5.4.4.2. Competitive Scenario
- 5.4.4.3. Regulatory Scenario
- 5.4.4.4. Reimbursement Scenario
- 5.4.4.5. France Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.5. Italy
- 5.4.5.1. Key Country Dynamics
- 5.4.5.2. Competitive Scenario
- 5.4.5.3. Regulatory Scenario
- 5.4.5.4. Reimbursement Scenario
- 5.4.5.5. Italy Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.6. Spain
- 5.4.6.1. Key Country Dynamics
- 5.4.6.2. Competitive Scenario
- 5.4.6.3. Regulatory Scenario
- 5.4.6.4. Reimbursement Scenario
- 5.4.6.5. Spain Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.7. Denmark
- 5.4.7.1. Key Country Dynamics
- 5.4.7.2. Competitive Scenario
- 5.4.7.3. Regulatory Scenario
- 5.4.7.4. Reimbursement Scenario
- 5.4.7.5. Denmark Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.8. Sweden
- 5.4.8.1. Key Country Dynamics
- 5.4.8.2. Competitive Scenario
- 5.4.8.3. Regulatory Scenario
- 5.4.8.4. Reimbursement Scenario
- 5.4.8.5. Sweden Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4.9. Norway
- 5.4.9.1. Key Country Dynamics
- 5.4.9.2. Competitive Scenario
- 5.4.9.3. Regulatory Scenario
- 5.4.9.4. Reimbursement Scenario
- 5.4.9.5. Norway Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Asia Pacific
- 5.5.1. Asia Pacific Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.2. Japan
- 5.5.2.1. Key Country Dynamics
- 5.5.2.2. Competitive Scenario
- 5.5.2.3. Regulatory Scenario
- 5.5.2.4. Reimbursement Scenario
- 5.5.2.5. Japan Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.3. China
- 5.5.3.1. Key Country Dynamics
- 5.5.3.2. Competitive Scenario
- 5.5.3.3. Regulatory Scenario
- 5.5.3.4. Reimbursement Scenario
- 5.5.3.5. China Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.4. India
- 5.5.4.1. Key Country Dynamics
- 5.5.4.2. Competitive Scenario
- 5.5.4.3. Regulatory Scenario
- 5.5.4.4. Reimbursement Scenario
- 5.5.4.5. India Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.5. South Korea
- 5.5.5.1. Key Country Dynamics
- 5.5.5.2. Competitive Scenario
- 5.5.5.3. Regulatory Scenario
- 5.5.5.4. Reimbursement Scenario
- 5.5.5.5. South Korea Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.6. Australia
- 5.5.6.1. Key Country Dynamics
- 5.5.6.2. Competitive Scenario
- 5.5.6.3. Regulatory Scenario
- 5.5.6.4. Reimbursement Scenario
- 5.5.6.5. Australia Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5.7. Thailand
- 5.5.7.1. Key Country Dynamics
- 5.5.7.2. Competitive Scenario
- 5.5.7.3. Regulatory Scenario
- 5.5.7.4. Reimbursement Scenario
- 5.5.7.5. Thailand Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Latin America
- 5.6.1. Latin America Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6.2. Brazil
- 5.6.2.1. Key Country Dynamics
- 5.6.2.2. Competitive Scenario
- 5.6.2.3. Regulatory Scenario
- 5.6.2.4. Reimbursement Scenario
- 5.6.2.5. Brazil Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6.3. Argentina
- 5.6.3.1. Key Country Dynamics
- 5.6.3.2. Competitive Scenario
- 5.6.3.3. Regulatory Scenario
- 5.6.3.4. Reimbursement Scenario
- 5.6.3.5. Argentina Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7. Middle East & Africa
- 5.7.1. Middle East & Africa Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7.2. South Africa
- 5.7.2.1. Key Country Dynamics
- 5.7.2.2. Competitive Scenario
- 5.7.2.3. Regulatory Scenario
- 5.7.2.4. Reimbursement Scenario
- 5.7.2.5. South Africa Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7.3. Saudi Arabia
- 5.7.3.1. Key Country Dynamics
- 5.7.3.2. Competitive Scenario
- 5.7.3.3. Regulatory Scenario
- 5.7.3.4. Reimbursement Scenario
- 5.7.3.5. Saudi Arabia Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7.4. UAE
- 5.7.4.1. Key Country Dynamics
- 5.7.4.2. Competitive Scenario
- 5.7.4.3. Regulatory Scenario
- 5.7.4.4. Reimbursement Scenario
- 5.7.4.5. UAE Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.7.5. Kuwait
- 5.7.5.1. Key Country Dynamics
- 5.7.5.2. Competitive Scenario
- 5.7.5.3. Regulatory Scenario
- 5.7.5.4. Reimbursement Scenario
- 5.7.5.5. Kuwait Dura Substitutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Market Participant Categorization
- 6.2. Key Company Profiles
- 6.2.1. Medtronic
- 6.2.1.1. Company Overview
- 6.2.1.2. Financial Performance
- 6.2.1.3. Service Benchmarking
- 6.2.1.4. Strategic Initiatives
- 6.2.2. B. Braun SE
- 6.2.2.1. Company Overview
- 6.2.2.2. Financial Performance
- 6.2.2.3. Service Benchmarking
- 6.2.2.4. Strategic Initiatives
- 6.2.3. Stryker
- 6.2.3.1. Company Overview
- 6.2.3.2. Financial Performance
- 6.2.3.3. Service Benchmarking
- 6.2.3.4. Strategic Initiatives
- 6.2.4. DePuy Synthes (Johnson & Johnson)
- 6.2.4.1. Company Overview
- 6.2.4.2. Financial Performance
- 6.2.4.3. Service Benchmarking
- 6.2.4.4. Strategic Initiatives
- 6.2.5. W. L. Gore & Associates, Inc.
- 6.2.5.1. Company Overview
- 6.2.5.2. Financial Performance
- 6.2.5.3. Service Benchmarking
- 6.2.5.4. Strategic Initiatives
- 6.2.6. Acera Surgical Inc.
- 6.2.6.1. Company Overview
- 6.2.6.2. Financial Performance
- 6.2.6.3. Service Benchmarking
- 6.2.6.4. Strategic Initiatives
- 6.2.7. Severn Healthcare Technologies Limited.
- 6.2.7.1. Company Overview
- 6.2.7.2. Financial Performance
- 6.2.7.3. Service Benchmarking
- 6.2.7.4. Strategic Initiatives
- 6.2.8. INTEGRA LIFESCIENCES
- 6.2.8.1. Company Overview
- 6.2.8.2. Financial Performance
- 6.2.8.3. Service Benchmarking
- 6.2.8.4. Strategic Initiatives
- 6.2.9. GUNZE LIMITED.
- 6.2.9.1. Company Overview
- 6.2.9.2. Financial Performance
- 6.2.9.3. Service Benchmarking
- 6.2.9.4. Strategic Initiatives